Description
Cortagen is a synthetic tetrapeptide bioregulator with the sequence Ala-Glu-Asp-Pro (AEDP), developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. Its sequence derives from directed amino acid analysis of Cortexin — a natural polypeptide preparation extracted from bovine cerebral cortex tissue — making Cortagen the defined synthetic analog of that earlier crude extract. Within the Khavinson bioregulator framework, Cortagen targets cortical neurons specifically, entering the cell nucleus and binding DNA promoter sequences to modulate gene expression in cerebral cortex tissue. This intranuclear mechanism places it in a distinct research class from CNS-active compounds like Semax, which targets BDNF expression through melanocortin receptor interaction at the cell surface. Researchers using Cortagen in specialty research peptide CNS models are studying gene-level cortical regulation rather than receptor-mediated neurotrophic signaling.
Key Characteristics
- Cerebral cortex tissue specificity — Cortagen targets cortical neurons through the same intranuclear DNA-binding mechanism as other Khavinson bioregulators, with gene regulatory effects documented in hippocampal and cortical tissue models in preclinical research
- Plasma half-life is under 5 minutes when administered parenterally — unusually short even among tetrapeptides, yet preclinical data documents biological effects persisting days to weeks after administration, consistent with epigenetic modulation rather than sustained receptor occupancy
- Differs from Pinealon (AEDG) by a single amino acid at the C-terminus — proline vs glycine — making the two compounds a useful pair for studying how minor sequence variation within the same bioregulator scaffold affects tissue targeting and gene expression specificity
- BDNF expression in hippocampal tissue and protection against oxidative neuronal injury have been documented in rodent models, though through a gene-regulatory mechanism distinct from the direct TrkB receptor pathway through which Semax exerts its neurotrophic effects
- All published evidence is preclinical and concentrated within the Khavinson research network; no independent Western clinical trials have been conducted
Handling and Storage
Store as lyophilized powder under refrigeration, away from heat, moisture, and light. Despite its very short plasma half-life once reconstituted, the lyophilized form is stable under proper storage conditions. Reconstitute immediately before use and avoid repeated freeze-thaw cycles.
FAQs
What is Cortagen?
Cortagen (AEDP) is a synthetic tetrapeptide bioregulator from the Khavinson series, derived through directed synthesis from Cortexin, a natural bovine cerebral cortex extract. It targets cortical neurons by entering the cell nucleus and modulating gene expression at specific DNA promoter sequences. Preclinical data documents effects on hippocampal BDNF expression and oxidative stress markers in neural tissue models. All evidence is preclinical.
How does Cortagen differ from Semax in CNS research models?
Both compounds influence BDNF-related signaling in neural tissue, but through fundamentally different mechanisms. Semax is an ACTH-derived peptide that interacts with melanocortin receptors and TrkB pathway activity at the cell surface. Cortagen bypasses surface receptors entirely, entering the nucleus directly to modulate gene transcription in cortical cells. Researchers select between them based on whether the study requires receptor-mediated neurotrophic signaling or intranuclear gene-regulatory modulation.
How does Cortagen relate to Pinealon within the Khavinson series?
Cortagen (AEDP) and Pinealon (AEDG) differ by a single amino acid at the C-terminus — proline vs glycine. Despite this minimal structural difference, the two compounds are associated with different tissue targets within the Khavinson framework: Cortagen for the cerebral cortex, Pinealon for broader brain tissue. Researchers studying Khavinson peptide structure-activity relationships use this pairing to examine how C-terminal variation within the same scaffold affects tissue specificity and gene expression profiles.
